3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
36
Sleep Initiation and Maintenance Disorders
1
Salivary Gland Neoplasms
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Neoplasm Metastasis
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castrate-sensitive Prostate Cancer
1
Low Risk Prostate Cancer
1
Fatigue
1
Depression
1
Adenocarcinoma
1
Interventions
Oxaliplatin
9
Capecitabine
9
Fluorouracil
7
pembrolizumab
6
Paclitaxel
6
Leucovorin
6
Cisplatin
5
zolbetuximab
4
trastuzumab deruxtecan
3
enzalutamide
3
durvalumab
3
cemiplimab
3
Trastuzumab
3
Gemcitabine
3
Docetaxel
3
fludarabine
2
darolutamide
2
Taxes
2
Ramucirumab
2
Radiotherapy, Image-Guided
2
Radiosurgery
2
Pemetrexed
2
Nivolumab
2
Irinotecan
2
Cyclophosphamide
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vistusertib
1
tucatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
apalutamide
×
90 days
×
Clear all
NCT06592924
2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3
Recruiting
830 enrolled